USA News Group News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 23, 2025 /CNW/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Cue Biopharma, Inc. (NASDAQ:CUE), Verastem, Inc. (NASDAQ:VSTM), Allogene Therapeutics, Inc. (NASDAQ:ALLO), and Perspective Therapeutics, Inc. (NYSE-American:CATX).
Read more at newswire.ca